Inhibition of Cytomegalovirus by Pentacta pygmaea Fucosylated Chondroitin Sulfate Depends on Its Molecular Weight
Open Access
Abstract
Many viruses attach to host cells by first interacting with cell surface proteoglycans containing heparan sulfate (HS) glycosaminoglycan chains and then by engaging with specific receptor, resulting in virus entry. In this project, HS–virus interactions were targeted by a new fucosylated chondroitin sulfate from the sea cucumber Pentacta pygmaea (PpFucCS) in order to block human cytomegalovirus (HCMV) entry into cells. Human foreskin fibroblasts were infected with HCMV in the presence of PpFucCS and its low molecular weight (LMW) fractions and the virus yield at five days post-infection was assessed. The virus attachment and entry into the cells were visualized by labeling the purified virus particles with a self-quenching fluorophore octadecyl rhodamine B (R18). The native PpFucCS exhibited potent inhibitory activity against HCMV specifically blocking virus entry into the cell and the inhibitory activities of the LMW PpFucCS derivatives were proportional to their chain lengths. PpFucCS and the derived oligosaccharides did not exhibit any significant cytotoxicity; moreover, they protected the infected cells from virus-induced lytic cell death. In conclusion, PpFucCS inhibits the entry of HCMV into cells and the high MW of this carbohydrate is a key structural element to achieve the maximal anti-viral effect. This new marine sulfated glycan can be developed into a potential prophylactic and therapeutic antiviral agent against HCMV infection.Keywords
Funding Information
- National Institutes of Health (1P20GM130460-01A1, 1R03NS110996-01A1, 80NSSC19K1603)
- University of Mississippi (1P20GM130460-01A1, 1R03NS110996-01A1, 80NSSC19K1603)
- National Aeronautics and Space Administration (1P20GM130460-01A1, 1R03NS110996-01A1, 80NSSC19K1603)
This publication has 44 references indexed in Scilit:
- A Peptide Inhibitor of Cytomegalovirus Infection from Human HemofiltrateAntimicrobial Agents and Chemotherapy, 2013
- Human cytomegalovirus entry into cellsCurrent Opinion in Virology, 2012
- Heparan Sulfate ProteoglycansCold Spring Harbor Perspectives in Biology, 2011
- Antiviral Drug Resistance of Human CytomegalovirusClinical Microbiology Reviews, 2010
- The Structure of Glycosaminoglycans and their Interactions with ProteinsChemical Biology & Drug Design, 2008
- Immunocompromised Hosts: Perspectives in the Treatment and Prophylaxis of Cytomegalovirus Disease in Solid‐Organ Transplant RecipientsClinical Infectious Diseases, 2008
- CNS Manifestations of Cytomegalovirus InfectionsCNS Drugs, 2002
- Neutralizing Antibodies Mechanism of Neutralization and Protective Activity Against HIV-1Immunologic Research, 2002
- Guide to Anticoagulant Therapy: HeparinCirculation, 2001
- Initiation of Human Cytomegalovirus Infection Requires Initial Interaction with Cell Surface Heparan SulfateVirology, 1993